Table 3.
Outcome, contraception type | Woman years | No with venous thrombosis | Adjusted rate ratio (95% CI)* | P value |
---|---|---|---|---|
All venous thrombosis: | ||||
COC with levonorgestrel and 30-40 µg oestrogen | 231 675 | 201 | 1.00 (reference) | — |
COC with norgestimate | 298 566 | 198 | 1.11 (0.91 to 1.35) | 0.305 |
Patch | 6178 | 7 | 1.85 (0.87 to 3.94) | 0.109 |
Vaginal ring | 50 334 | 55 | 1.81 (1.34 to 2.44) | 0.0001 |
Implant | 29 497 | 15 | 0.88 (0.52 to 1.48) | 0.623 |
Levonorgestrel IUS | 239 841 | 88 | 0.34 (0.26 to 0.43) | <0.001 |
Confirmed events: | ||||
COC with levonorgestrel and 30-40 µg oestrogen | 231 675 | 144 | 1.00 (reference) | — |
COC with norgestimate | 298 566 | 135 | 1.11 (0.88 to 1.41) | 0.378 |
Patch | 6178 | 6 | 2.46 (1.09 to 5.58) | 0.031 |
Vaginal ring | 50 334 | 39 | 2.02 (1.41 to 2.89) | 0.0001 |
Implant | 29 497 | 5 | 0.44 (0.18 to 1.07) | 0.070 |
Levonorgestrel IUS | 239 841 | 33 | 0.18 (0.12 to 0.26) | <0.001 |
Confirmed events adjusted for length of use: | ||||
COC with levonorgestrel and 30-40 µg oestrogen | 231 675 | 144 | 1.00 (reference) | — |
COC with norgestimate | 298 566 | 135 | 1.09 (0.86 to 1.38) | 0.465 |
Patch | 6178 | 6 | 2.31 (1.02 to 5.23) | 0.045 |
Vaginal ring | 50 334 | 39 | 1.90 (1.33 to 2.71) | 0.001 |
Implant | 29 497 | 5 | 0.43 (0.18 to 1.05) | 0.064 |
Levonorgestrel IUS | 239 841 | 33 | 0.18 (0.12 to 0.26) | <0.001 |
Patch=transdermal contraceptive patch (EVRA; Johnson & Johnson, NJ, USA); implant=subcutaneous implant (Implanon; MSD; NJ, USA); vaginal ring=combined hormonal vaginal ring (NuvaRing; MSD, NJ, USA); levonorgestrel IUS=levonorgestrel intrauterine system (Mirena; Bayer Pharma, Berlin, Germany).
*Adjusted for age, calendar year, and education.